Animesh Das*

Department of Pharmacy Practice, Rajiv Gandhi University of Health Sciences, India

*Corresponding Author: Animesh Das, Department of Pharmacy Practice, Rajiv Gandhi University of Health Sciences, India.

Received: February 17, 2026 Published: February 28, 2026

Abstract

The continuous evolution of drug delivery systems represents one of the most dynamic and impactful areas of pharmaceutical sciences. Conventional dosage forms, while effective in many clinical settings, often suffer from limitations such as rapid systemic distribution, short half-life, non-specific targeting, and increased risk of adverse effects. These challenges are particularly evident in chronic disorders and oncological conditions, where prolonged therapy and precise targeting are critical for therapeutic success. In response to these limitations, contemporary research has increasingly focused on advanced carrier platforms capable of controlled, sustained, and site-specific drug delivery. Among the most promising systems are polymeric nanoparticles, liposomal formulations, and thermoresponsive hydrogels [1,5].

Polymeric nanoparticles have emerged as versatile and highly tunable carriers for drug delivery. Recent progress in the development of multi-arm polycaprolactone-based nanoparticles has highlighted the importance of polymer architecture in influencing drug delivery performance. Unlike traditional linear polymers, multi-arm polymers possess branched chain structures that improve their physicochemical and biological properties. These architectures allow for enhanced drug loading efficiency, smaller and more uniform particle size, improved colloidal stability, and prolonged drug release profiles. The reduced critical micellar concentration associated with such systems contributes to improved stability under physiological conditions, minimizing premature drug leakage. Furthermore, systematic evaluation of structure–property relationships, including chain topology and self-assembly dynamics, enables rational optimization of nanocarriers. Through deliberate design adjustments, polymeric nanoparticles can be engineered to achieve sustained and predictable release kinetics suitable for long-term management of chronic diseases and cancer [1].

Targeted polymeric nanoparticles represent another major advancement in precision medicine. Cancer therapy, in particular, continues to face the dual challenge of maximizing cytotoxicity against tumor cells while minimizing systemic toxicity. Conventional chemotherapeutic agents often affect healthy tissues, leading to severe adverse reactions. Biocompatible and biodegradable polymers, including chitosan, alginate, cyclodextrin, polylactic acid, polycaprolactone, and polyethylene glycol, have been widely explored for nanoparticle fabrication. These materials not only enhance drug solubility and stability but also provide opportunities for surface modification and ligand attachment. By incorporating tumor-specific targeting moieties, nanoparticles can selectively accumulate in malignant tissues through passive and active targeting mechanisms. Such strategies improve therapeutic concentration at the desired site while reducing off-target exposure. The development of tumor-targeted nanoparticles illustrates how nanotechnology can bridge the gap between pharmacokinetics and pharmacodynamics to achieve improved clinical outcomes [2].

Liposomal drug delivery systems have similarly contributed to advancements in controlled and localized therapy. Composed of phospholipid bilayers resembling biological membranes, liposomes can encapsulate both hydrophilic and lipophilic drugs. Their structural similarity to cellular membranes enhances biocompatibility and reduces immunogenicity. Liposomes offer protection against drug degradation and can modulate pharmacokinetic profiles, thereby reducing toxicity. However, standalone liposomal systems may face limitations related to mechanical strength, drug leakage, and rapid clearance. To address these challenges, integration of liposomes into hydrogel matrices has been explored as a hybrid approach [3,4].

Hydrogels are three-dimensional crosslinked polymer networks capable of absorbing substantial quantities of water while maintaining structural integrity. Their high-water content, porosity, and flexibility make them suitable for biomedical applications. When liposomes are embedded within hydrogel matrices, the resulting composite systems combine the protective encapsulation capacity of liposomes with the controlled release behavior of hydrogels. Drug release can be regulated through swelling, diffusion, and matrix relaxation mechanisms. These liposome-hydrogel hybrids demonstrate improved mechanical stability, sustained release kinetics, and enhanced localized delivery [3,4]. In chronic wound management, oncological therapy, and localized infections, such systems may reduce dosing frequency and improve patient compliance. Additionally, evaluation of rheological properties ensures appropriate consistency, injectability, and stability for clinical application [4].

Recent investigations have also demonstrated that liposomes incorporated into chitosan-based hydrogels exhibit non-Fickian drug release behavior. This phenomenon indicates that drug release is governed by a combination of diffusion processes and polymer relaxation dynamics. Such dual-mechanism release profiles contribute to more predictable and sustained therapeutic effects. Importantly, the structural integrity of the hydrogel matrix remains intact during drug delivery, maintaining stability and functionality over extended periods. This synergy between nanoscale vesicles and polymer networks underscores the potential of composite systems in achieving advanced site-specific therapy [4].

Thermoresponsive hydrogels represent an additional innovation in controlled drug delivery technology. These smart materials undergo temperature-induced sol–gel transitions, remaining in liquid form at lower temperatures and transforming into a semi-solid gel at physiological temperature. This property enables minimally invasive administration through injection, followed by in situ gel formation at the target site. Once formed, the gel acts as a depot that gradually releases the encapsulated drug. Such temperature-triggered systems are particularly advantageous for localized cancer treatment, where sustained release at the tumor site can reduce systemic exposure and associated toxicity [5].

Ongoing research seeks to enhance the mechanical strength, responsiveness, and functional versatility of thermosensitive hydrogels. Advanced crosslinking strategies have improved structural stability, while incorporation of multifunctional components has enabled better control over drug release rates and targeting capabilities. By fine-tuning polymer composition and network density, researchers can modulate degradation rate and release kinetics according to therapeutic requirements. These developments reflect the growing importance of smart biomaterials capable of responding to physiological stimuli [1].

The integration of polymeric nanoparticles, liposomal carriers, and thermoresponsive hydrogels signifies a comprehensive and multidimensional approach to modern drug delivery. Rather than relying on a single carrier system, contemporary strategies increasingly combine complementary technologies to optimize stability, targeting efficiency, and release control. Such integrated platforms aim to deliver the right drug concentration at the correct anatomical site over a defined therapeutic window. Achieving this precision requires meticulous design, rigorous optimization, and comprehensive physicochemical and biological evaluation [1,5].

Ultimately, advances in nanocarrier architecture, hybrid delivery systems, and smart responsive materials demonstrate how pharmaceutical sciences continue to move toward precision medicine. By strengthening understanding of structure–property relationships, improving drug loading capacity, ensuring mechanical stability, and refining release mechanisms, researchers can develop delivery systems that are safer, more effective, and patient-centered. Continued interdisciplinary collaboration between pharmaceutics, materials science, molecular biology, and clinical research will further accelerate translation from laboratory innovation to clinical application. These efforts are essential for improving quality of life and achieving sustained therapeutic success in chronic and oncological diseases [1,5].

References

1. El Yousfi R., et al. “Recent advances in nanoparticle development for drug delivery: a comprehensive review of polycaprolactone-based multi-arm architectures”. Polymers8 (2023): 1835.
2. Srinivasan MK and Prasad M. “Recent advances in tumor targeted polymeric nanoparticles for HNC treatment: Enhancing therapeutic efficacy via engineered and biocompatible drug delivery systems”. Journal of Oral Biology and Craniofacial Research6 (2025): 1316-1330.
3. Binaymotlagh R., et al. “Liposome–hydrogel composites for controlled drug delivery applications”. Gels 4 (2024): 284.
4. Braido B., et al. “Liposomes-in-hydrogel for topical drug delivery: Mechanical, kinetic, and biological insights”. Journal of Drug Delivery Science and Technology 6 (2025): 107380.
5. Zuo H., et al. “Recent Advances in Smart Stimulus-Responsive Hydrogels for Precision Drug Delivery in Tumours”. Gels 2 (2026): 98.

Citation

Citation: Animesh Das. “Design, Optimisation, and Comprehensive Evaluation of Polymeric Nanoparticles, Targeted Liposomal Systems, and Thermoresponsive Hydrogels for Advanced Controlled and Site-Specific Drug Delivery in Chronic and Oncological Diseases". Acta Scientific Pharmaceutical Sciences 10.3 (2026): 11-13.

Copyright

Copyright: © 2026 Animesh Das. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.